Form 4: Cardiff Oncology Director Lale White Granted Stock Options Under 10b5-1 Plan

Cardiff Oncology, Inc. Director Lale White was granted 40,565 stock options with an exercise price of $3.16, exercisable from June 26, 2026, as part of a Rule 10b5-1 plan.

Summary

• Lale White, a Director of Cardiff Oncology, Inc. (CRDF), was granted 40,565 stock options.
• The stock options have an exercise price of $3.16 per share.
• These options become exercisable on June 26, 2026, and are set to expire on June 26, 2035.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase or sale plan.
• Following this reported transaction, Lale White beneficially owns a total of 158,681 derivative securities, specifically stock options.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns management's interests with shareholders, which is generally a neutral to slightly positive signal. The transaction being under a 10b5-1 plan also adds a layer of transparency and pre-planning.

Positives

• The grant of stock options to a director helps align their financial interests with those of the company's shareholders, incentivizing long-term performance and value creation.
• The transaction was conducted under a Rule 10b5-1 plan, which demonstrates a pre-planned approach to equity transactions, enhancing transparency and mitigating concerns about insider trading.

Future Outlook

This Form 4 does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports an insider transaction.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, as well as other sectors, to attract, retain, and incentivize key personnel by aligning their financial interests with the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, particularly in the biotech sector where long-term value creation is tied to drug development milestones.
• Specific comparable companies or projects are not mentioned in this filing, but such grants are typical for directors at companies like Amgen, Gilead Sciences, or Biogen, where equity compensation forms a significant part of executive and director remuneration.
• The exercise price of $3.16 is based on the market price at the time of grant, which is standard for incentive stock options.

Related Party Transactions

• This document reports a related party transaction, specifically the grant of stock options as compensation to Lale White, a Director of Cardiff Oncology, Inc.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term share value. It also represents a potential future dilution if options are exercised, though this is a standard aspect of equity compensation.
• Employees: No direct impact on general employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

Cardiff Oncology, CRDF, Lale White, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Rule 10b5-1